Wednesday 23 June

Session 1: Regulatory requirements for early clinical testing of novel HCV antiviral drugs

Invited lecture: The US (FDA) regulatory perspective

J. Murray

Pres.

Invited lecture: A European Perspective

J.M. Pawlotsky

Pres.

Session 2: Clinical Pharmacology - Polymerase Inhibitors

Invited lecture: Ribavirin – still needed, but how does it work?

J. Feld

Pres.

Ribavirin mono-, di-, and triphosphate concentrations in the peripheral blood mononuclear and red blood cells of Hepatitis C virus infected persons

J. Kiser

Pres.

Ribavirin plasma concentrations in chronic hepatitis C infected patients with or without HIV co-infection: is there a difference?

K. de Kanter

Pres.

PK/VK assessment from PROGRESS: Induction dosing of PegIFN a-2a (40KD) and/or high-dose RBV in G1 CHC patients with difficult-to-treat characteristics

P. Morcos

n.a

Pharmacokinetics, safety and toleration of multiple oral doses of filibuvir in elderly healthy volunteers

V. Purohit

Pres.

Pharmacokinetics, safety and toleration of a single oral dose of filibuvir in subjects with hepatic impairment

V. Purohit

IDX375, a novel non-nucleoside HCV polymerase inhibitor: safety, tolerability and pharmacokinetics (PK) in a phase I clinical study

XJ. Zhou

Pres.

Session 3: Aspects of combination therapy

Invited lecture: Can combination therapy cure HCV infection? Key virological factors for consideration

I. Najera

n.a

Invited lecture: Opening the door to future treatment regimens in HCV with combinations

P. Smith

n.a

Applications of discrete-event dynamic simulation in HCV treatment dynamics

B. Adiwijaya

n.a

Overcoming HCV drug resistance with Direct Acting Antivirals (DAA) thru mathematical modeling

E. Tafoya

n.a

Session 4: Clinical Pharmacology - Protease Inhibitors

Invited lecture: Pharmacokinetic boosting of HCV protease inhibitors with Ritonavir: More than it seems?

D. Kempf

Pres.

Invited lecture: Development of Cobicistat for boosting antiretrovirals

A. Mathias

n.a

Lack of a significant food interaction following administration of TMC435 oral capsule formulation

V. Sekar

n.a

Pharmacokinetics of MK-7009, a novel inhibitor of the hepatitis C virus NS3/4a protease, in healthy Japanese compared with healthy Caucasian subjects

C. Nishida

n.a

The pharmacokinetic (PK) interaction between esomeprazole and the investigational HCV protease inhibitor telaprevir

R. van Heeswijk

n.a

The pharmacokinetic (PK) interaction between escitalopram and the investigational HCV protease inhibitor telaprevir

R. van Heesijk

IDX320, a novel macrocyclic HCV protease inhibitor: safety, tolerability and pharmacokinetics (PK) in a phase I clinical study

D. Mayers

n.a